Telix Doses First US Patients With FDA-Approved Brain Cancer Imaging Drug
MT newswire2026/10/06 11:2507:25 AM EDT, 10/06/2026 (MT Newswires) -- Telix Pharmaceuticals (TLX) said Tuesday it administered the first US doses of Pixclara, a Food and Drug Administration-approved positron emission tomography imaging drug for brain cancer imaging. The initial doses took place at medical centers in Cleveland and Indianapolis, starting the product's commercial availability in the country, the company said. PharmaLogic will be the manufacturing and pharmacy distribution partner to supply finished unit doses to the market, Telix said. The drug, also known as floretyrosine F-18, is used to help differentiate recurrent or progressive glioma from treatment-related changes in patients aged one month and above, it said.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
